Pieter A. Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pieter A. Cohen has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
John C. Travis
NSF International, Ann Harbor, Michigan
9 shared publicationsBastiaan J. Venhuis
Health Protection Center, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
7 shared publicationsBharathi Avula
National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University
7 shared publicationsIkhlas Khan
National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University
6 shared publicationsKumar Katragunta
National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University
4 shared publicationsRoy Gerona
Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, CA, USA
3 shared publications
Latest Publications
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (6) , 898-900
U.S. Emergency Department Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022–2023
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (6) , 898-900
U.S. Emergency Department Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022–2023
- Open Access
- 3 July 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (7) , e2323879
Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements
Since the US Food and Drug Administration (FDA) banned ephedra from dietary supplements in 2004, supplement manufacturers have promoted a complex variety of alternative botanical compounds for sports enhancement. Extracts of Rauwolfia vomitoria containing α-yohimbine, the caffeine-like compound methylliberine, the partial β2-agonist halostachine, the plant steroid turkesterone, and norepinephrine-like octopamine are all found in plants and are promoted in dietary supplements for their stimulant or anabolic effects.1-3
- 3 July 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (7) , e2323879
Open AccessPresence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements
Since the US Food and Drug Administration (FDA) banned ephedra from dietary supplements in 2004, supplement manufacturers have promoted a complex variety of alternative botanical compounds for sports enhancement. Extracts of Rauwolfia vomitoria containing α-yohimbine, the caffeine-like compound methylliberine, the partial β2-agonist halostachine, the plant steroid turkesterone, and norepinephrine-like octopamine are all found in plants and are promoted in dietary supplements for their stimulant or anabolic effects.1-3
- Open Access
- 25 April 2023
- Published by American Medical Association (AMA)
- Vol. 329 (16) , 1401-1402
Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US
Prior to the COVID-19 pandemic, melatonin was used by an estimated 1.3% of children in the US, most commonly for sleep, stress, and relaxation.1,2 Despite the lack of high-quality evidence to support melatonin’s efficacy for these indications in healthy children, use increased during the COVID-19 pandemic. Calls for pediatric melatonin ingestions to US Poison Control Centers increased 530% from 2012 to 2021 and were associated with 27 795 emergency department and clinic visits, 4097 hospitalizations, 287 intensive care unit admissions, and 2 deaths.3
- 25 April 2023
- Published by American Medical Association (AMA)
- Vol. 329 (16) , 1401-1402
Open AccessQuantity of Melatonin and CBD in Melatonin Gummies Sold in the US
Prior to the COVID-19 pandemic, melatonin was used by an estimated 1.3% of children in the US, most commonly for sleep, stress, and relaxation.1,2 Despite the lack of high-quality evidence to support melatonin’s efficacy for these indications in healthy children, use increased during the COVID-19 pandemic. Calls for pediatric melatonin ingestions to US Poison Control Centers increased 530% from 2012 to 2021 and were associated with 27 795 emergency department and clinic visits, 4097 hospitalizations, 287 intensive care unit admissions, and 2 deaths.3
- Open Access
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 79 (10) , 1085-1086
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database
This case series assesses the levels of levodopa in Mucuna pruriens supplements available in the US that are included in the National Institutes of Health Dietary Supplement Label Database.
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 79 (10) , 1085-1086
Open AccessLevodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database
This case series assesses the levels of levodopa in Mucuna pruriens supplements available in the US that are included in the National Institutes of Health Dietary Supplement Label Database.
- 12 August 2022
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (10) , 1156-1158
The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements
Centrophenoxine (meclofenoxate) is prescribed in China and elsewhere to treat a variety of conditions including alcoholism and dementia, but the US Food and Drug Administration has not approved the...
- 12 August 2022
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (10) , 1156-1158
The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements
Centrophenoxine (meclofenoxate) is prescribed in China and elsewhere to treat a variety of conditions including alcoholism and dementia, but the US Food and Drug Administration has not approved the...
- Open Access
- 26 July 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (4) , 393-395
Recalls, Availability, and Content of Dietary Supplements Following FDA Warning Letters
Some dietary supplements are adulterated with novel and unapproved stimulants. These analogues of amphetamine, ephedrine, and other drugs have been linked to serious health risks, including hemorrhagic stroke and sudden death. The US Food and Drug Administration (FDA) is responsible for removing these hazardous supplements from the market, and the agency has attempted to do so by issuing warning letters to manufacturers (Supplement).1-3
- 26 July 2022
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (4) , 393-395
Open AccessRecalls, Availability, and Content of Dietary Supplements Following FDA Warning Letters
Some dietary supplements are adulterated with novel and unapproved stimulants. These analogues of amphetamine, ephedrine, and other drugs have been linked to serious health risks, including hemorrhagic stroke and sudden death. The US Food and Drug Administration (FDA) is responsible for removing these hazardous supplements from the market, and the agency has attempted to do so by issuing warning letters to manufacturers (Supplement).1-3
- 22 September 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (4) , 486-488
Quantity of phenibut in dietary supplements before and after FDA warnings
Phenibut is used to treat anxiety, insomnia, alcohol withdrawal and other conditions in Russia. The drug, however, has abuse potential and may cause lethargy, delirium, psychosis and coma. In the U...
- 22 September 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 60 (4) , 486-488
Quantity of phenibut in dietary supplements before and after FDA warnings
Phenibut is used to treat anxiety, insomnia, alcohol withdrawal and other conditions in Russia. The drug, however, has abuse potential and may cause lethargy, delirium, psychosis and coma. In the U...
- 1 June 2021
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 11 (3) , e303-e307
Five Unapproved Drugs Found in Cognitive Enhancement Supplements
Objective To identify the presence of unapproved pharmaceutical drugs in over-the-counter dietary supplements marketed to improve memory and cognitive function. Methods Supplements were identified by searching 2 supplement databases for products labeled as containing omberacetam, aniracetam, phenylpiracetam, or oxiracetam, 4 drugs not approved for human use in the United States. Products were purchased online and analyzed using nontargeted liquid chromatography-quadrupole time-of-flight mass spectrometry methods. Results In the 10 products tested, omberacetam and aniracetam were detected along with 3 additional unapproved drugs (i.e., phenibut, vinpocetine and picamilon). By consuming recommended serving sizes, consumers could be exposed to pharmaceutical-level dosages of drugs including a maximum of 40.6 ± 0.4 mg omberacetam (typical pharmacologic dose of 10 mg), 502 ± 0.8 mg of aniracetam (typical pharmacologic dose 200–750 mg), 15.4 ± 0.3 mg of phenibut (typical pharmacologic dose 250–500 mg), 4.3 ± 0.1 mg of vinpocetine (typical pharmacologic dose 5–40 mg), and 90.1 ± 0.7 mg of picamilon (typical pharmacologic dose 50–200 mg). Several detected drugs were not declared on the label, and several declared drugs were not detected in the products. For those products with drug quantities provided on the labels, 75% (9/12) of declared quantities were inaccurate. Consumers could be exposed to up to four-fold greater than pharmaceutical dosages and as many as 4 unapproved drugs when using individual products. Conclusions Over-the-counter cognitive enhancement supplements may contain multiple unapproved drugs. The health effects of consuming untested combinations of unapproved drugs at unpredictable dosages without clinician oversight in supplements are unknown.
- 1 June 2021
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 11 (3) , e303-e307
Five Unapproved Drugs Found in Cognitive Enhancement Supplements
Objective To identify the presence of unapproved pharmaceutical drugs in over-the-counter dietary supplements marketed to improve memory and cognitive function. Methods Supplements were identified by searching 2 supplement databases for products labeled as containing omberacetam, aniracetam, phenylpiracetam, or oxiracetam, 4 drugs not approved for human use in the United States. Products were purchased online and analyzed using nontargeted liquid chromatography-quadrupole time-of-flight mass spectrometry methods. Results In the 10 products tested, omberacetam and aniracetam were detected along with 3 additional unapproved drugs (i.e., phenibut, vinpocetine and picamilon). By consuming recommended serving sizes, consumers could be exposed to pharmaceutical-level dosages of drugs including a maximum of 40.6 ± 0.4 mg omberacetam (typical pharmacologic dose of 10 mg), 502 ± 0.8 mg of aniracetam (typical pharmacologic dose 200–750 mg), 15.4 ± 0.3 mg of phenibut (typical pharmacologic dose 250–500 mg), 4.3 ± 0.1 mg of vinpocetine (typical pharmacologic dose 5–40 mg), and 90.1 ± 0.7 mg of picamilon (typical pharmacologic dose 50–200 mg). Several detected drugs were not declared on the label, and several declared drugs were not detected in the products. For those products with drug quantities provided on the labels, 75% (9/12) of declared quantities were inaccurate. Consumers could be exposed to up to four-fold greater than pharmaceutical dosages and as many as 4 unapproved drugs when using individual products. Conclusions Over-the-counter cognitive enhancement supplements may contain multiple unapproved drugs. The health effects of consuming untested combinations of unapproved drugs at unpredictable dosages without clinician oversight in supplements are unknown.
- 26 March 2021
- Published by Springer Nature in Journal of Immigrant and Minority Health
- Vol. 23 (5) , 1110-1115
Risk Factors for Hospitalization Among Patients with COVID-19 at a Community Ambulatory Clinic in Massachusetts During the Initial Pandemic Surge
Among patients with COVID-19 evaluated in outpatient settings, factors associated with hospitalization remain poorly understood. Multivariable regressions were used to assess sociodemographic and clinical factors associated with increased odds of hospitalization among patients with confirmed COVID-19 between March 18, 2020 through April 25, 2020 at a community-based outpatient clinic in Massachusetts. Older age, BMI ≥ 25, self-reported dizziness/lightheadedness, temperature ≥ 99.5°F, tachycardia, and oxygen saturation < 95% were associated with increased odds of hospitalization after adjustment for age, sex, and BMI. There was also an association between speaking Spanish as primary language and increased odds of hospitalization (compared to English, adjusted OR = 2.99 [95% CI 1.39, 6.39]). Speaking Portuguese as primary language was not associated with increased odds of hospitalization (compared to English, adjusted OR = 1.83 [0.78, 4.28]). In addition to several clinical risk factors established among inpatients, our study found that primarily speaking Spanish, but not Portuguese, was a marker of hospitalization risk among a diverse outpatient cohort of patients with COVID-19.
- 26 March 2021
- Published by Springer Nature in Journal of Immigrant and Minority Health
- Vol. 23 (5) , 1110-1115
Risk Factors for Hospitalization Among Patients with COVID-19 at a Community Ambulatory Clinic in Massachusetts During the Initial Pandemic Surge
Among patients with COVID-19 evaluated in outpatient settings, factors associated with hospitalization remain poorly understood. Multivariable regressions were used to assess sociodemographic and clinical factors associated with increased odds of hospitalization among patients with confirmed COVID-19 between March 18, 2020 through April 25, 2020 at a community-based outpatient clinic in Massachusetts. Older age, BMI ≥ 25, self-reported dizziness/lightheadedness, temperature ≥ 99.5°F, tachycardia, and oxygen saturation < 95% were associated with increased odds of hospitalization after adjustment for age, sex, and BMI. There was also an association between speaking Spanish as primary language and increased odds of hospitalization (compared to English, adjusted OR = 2.99 [95% CI 1.39, 6.39]). Speaking Portuguese as primary language was not associated with increased odds of hospitalization (compared to English, adjusted OR = 1.83 [0.78, 4.28]). In addition to several clinical risk factors established among inpatients, our study found that primarily speaking Spanish, but not Portuguese, was a marker of hospitalization risk among a diverse outpatient cohort of patients with COVID-19.
- 23 March 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59 (11) , 975-981
Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine
Weight loss and sports supplements containing deterenol have been associated with serious adverse events including cardiac arrest.To determine the presence and quantity of experimental stimulants i...
- 23 March 2021
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59 (11) , 975-981
Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine
Weight loss and sports supplements containing deterenol have been associated with serious adverse events including cardiac arrest.To determine the presence and quantity of experimental stimulants i...